Skip to main content
NewslettersWatchlist

Ocugen Inc(OCGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.9130
Day High0.9130
Open:0.9130
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
GlobeNewswire
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Barchart
Wall Street Expects These 2 Under-the-Radar Growth Stocks to Outperform
Motley Fool
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
GlobeNewswire
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
GlobeNewswire
Ocugen Secures $30 Million in Debt Funding
GlobeNewswire
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
GlobeNewswire
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
GlobeNewswire
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
GlobeNewswire
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
GlobeNewswire
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
Barchart
2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%
Motley Fool
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
Motley Fool
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
TheNewswire.com
OCGN DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
OCGN DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
OCGN FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
OCGN LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
TheNewswire.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN

Profile

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.